JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

Search

Innoviva Inc

Avatud

SektorTervishoid

17.55 -1.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.38

Max

17.8

Põhinäitajad

By Trading Economics

Sissetulek

110M

64M

Müük

12M

100M

P/E

Sektori keskmine

30.193

37.461

Kasumimarginaal

63.508

Töötajad

127

EBITDA

111M

84M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+114.81% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-82M

1.1B

Eelmine avamishind

18.68

Eelmine sulgemishind

17.55

Uudiste sentiment

By Acuity

34%

66%

97 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Innoviva Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. okt 2025, 23:25 UTC

Tulu

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. okt 2025, 23:18 UTC

Tulu

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. okt 2025, 22:20 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. okt 2025, 22:13 UTC

Tulu

Wal-Mart de Mexico Net Profit Falls in 3Q

28. okt 2025, 21:38 UTC

Tulu

Correction to Visa Sales Jump Article

28. okt 2025, 21:17 UTC

Tulu

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. okt 2025, 21:07 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- Update

28. okt 2025, 21:02 UTC

Tulu

Mondelez Tempers Outlook as Costs Rise

28. okt 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. okt 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. okt 2025, 23:02 UTC

Tulu

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. okt 2025, 23:01 UTC

Tulu

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. okt 2025, 22:46 UTC

Tulu

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. okt 2025, 22:45 UTC

Tulu

SK Hynix 3Q Net KRW12.6T >000660.SE

28. okt 2025, 22:44 UTC

Tulu

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. okt 2025, 22:43 UTC

Tulu

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. okt 2025, 22:42 UTC

Tulu

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. okt 2025, 22:20 UTC

Tulu

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. okt 2025, 22:02 UTC

Tulu

Review & Preview: Earnings Extravaganza -- Barrons.com

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. okt 2025, 21:20 UTC

Tulu

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. okt 2025, 21:19 UTC

Tulu

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. okt 2025, 21:18 UTC

Tulu

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Võrdlus sarnastega

Hinnamuutus

Innoviva Inc Prognoos

Hinnasiht

By TipRanks

114.81% tõus

12 kuu keskmine prognoos

Keskmine 38 USD  114.81%

Kõrge 55 USD

Madal 17 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Innoviva Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

3

Osta

0

Hoia

1

Müü

Tehniline skoor

By Trading Central

18.57 / 18.75Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

97 / 373 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat